Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EOG Resources Inc (EOG) vs Summit Therapeutics Inc (SMMT) Price & Performance

EOG Resources IncTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

EOG Resources Inc vs Summit Therapeutics Inc — how do they compare? EOG Resources Inc trades at $144 (market cap $75.22B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: EOG Resources Inc is far larger — about 6.2× Summit Therapeutics Inc's market cap, and EOG Resources Inc pays a 2.85% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

EOGSMMT
Market Cap
$75.22B$12.06B
Sector
EnergyHealth
52-Week High
$149.89$26.98
52-Week Low
$101.78$12.55
Enterprise Value
$78.56B$11.39B
Dividend Yield
2.85%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EOG Resources Inc

EOG Resources trades at $142.93, up 0.5% today, with a bullish technical outlook and strong fundamentals. The stock exhibits robust profitability with a 25.81% net income margin and 22.51% ROE, supported by three consecutive quarterly earnings beats. Analysts are overwhelmingly positive with a $157.88 consensus target and no sell ratings. Recent news highlights record Q2 2026 earnings, cost discipline, and promising international exploration.

The outlook for EOG is favorable, driven by strong cash flow generation, shareholder returns, and operational efficiency. Key risks include oil price volatility and capital expenditure intensity. With solid institutional support and a discounted valuation, the stock presents a compelling opportunity for growth-oriented investors seeking energy exposure.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About EOG Resources Inc

EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.

Read more on EOG

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT